These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 31495749)

  • 1. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
    Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Cancer Risk by BRCA2 Genomic Regions.
    Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Tripathi V; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
    Eur Urol; 2020 Oct; 78(4):494-497. PubMed ID: 32532514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
    Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; ; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H
    JAMA; 2017 Jun; 317(23):2402-2416. PubMed ID: 28632866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.
    Oh M; Alkhushaym N; Fallatah S; Althagafi A; Aljadeed R; Alsowaida Y; Jeter J; Martin JR; Babiker HM; McBride A; Abraham I
    Prostate; 2019 Jun; 79(8):880-895. PubMed ID: 30900310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study.
    Bancroft EK; Page EC; Castro E; Lilja H; Vickers A; Sjoberg D; Assel M; Foster CS; Mitchell G; Drew K; Mæhle L; Axcrona K; Evans DG; Bulman B; Eccles D; McBride D; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Cybulski C; Wokolorczyk D; Selkirk C; Hulick PJ; Bojesen A; Skytte AB; Lam J; Taylor L; Oldenburg R; Cremers R; Verhaegh G; van Zelst-Stams WA; Oosterwijk JC; Blanco I; Salinas M; Cook J; Rosario DJ; Buys S; Conner T; Ausems MG; Ong KR; Hoffman J; Domchek S; Powers J; Teixeira MR; Maia S; Foulkes WD; Taherian N; Ruijs M; Helderman-van den Enden AT; Izatt L; Davidson R; Adank MA; Walker L; Schmutzler R; Tucker K; Kirk J; Hodgson S; Harris M; Douglas F; Lindeman GJ; Zgajnar J; Tischkowitz M; Clowes VE; Susman R; Ramón y Cajal T; Patcher N; Gadea N; Spigelman A; van Os T; Liljegren A; Side L; Brewer C; Brady AF; Donaldson A; Stefansdottir V; Friedman E; Chen-Shtoyerman R; Amor DJ; Copakova L; Barwell J; Giri VN; Murthy V; Nicolai N; Teo SH; Greenhalgh L; Strom S; Henderson A; McGrath J; Gallagher D; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Costello P; Eyfjord J; Rothwell J; Falconer A; Gronberg H; Hamdy FC; Johannsson O; Khoo V; Kote-Jarai Z; Lubinski J; Axcrona U; Melia J; McKinley J; Mitra AV; Moynihan C; Rennert G; Suri M; Wilson P; Killick E; ; Moss S; Eeles RA
    Eur Urol; 2014 Sep; 66(3):489-99. PubMed ID: 24484606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
    Page EC; Bancroft EK; Brook MN; Assel M; Hassan Al Battat M; Thomas S; Taylor N; Chamberlain A; Pope J; Raghallaigh HN; Evans DG; Rothwell J; Maehle L; Grindedal EM; James P; Mascarenhas L; McKinley J; Side L; Thomas T; van Asperen C; Vasen H; Kiemeney LA; Ringelberg J; Jensen TD; Osther PJS; Helfand BT; Genova E; Oldenburg RA; Cybulski C; Wokolorczyk D; Ong KR; Huber C; Lam J; Taylor L; Salinas M; Feliubadaló L; Oosterwijk JC; van Zelst-Stams W; Cook J; Rosario DJ; Domchek S; Powers J; Buys S; O'Toole K; Ausems MGEM; Schmutzler RK; Rhiem K; Izatt L; Tripathi V; Teixeira MR; Cardoso M; Foulkes WD; Aprikian A; van Randeraad H; Davidson R; Longmuir M; Ruijs MWG; Helderman van den Enden ATJM; Adank M; Williams R; Andrews L; Murphy DG; Halliday D; Walker L; Liljegren A; Carlsson S; Azzabi A; Jobson I; Morton C; Shackleton K; Snape K; Hanson H; Harris M; Tischkowitz M; Taylor A; Kirk J; Susman R; Chen-Shtoyerman R; Spigelman A; Pachter N; Ahmed M; Ramon Y Cajal T; Zgajnar J; Brewer C; Gadea N; Brady AF; van Os T; Gallagher D; Johannsson O; Donaldson A; Barwell J; Nicolai N; Friedman E; Obeid E; Greenhalgh L; Murthy V; Copakova L; Saya S; McGrath J; Cooke P; Rønlund K; Richardson K; Henderson A; Teo SH; Arun B; Kast K; Dias A; Aaronson NK; Ardern-Jones A; Bangma CH; Castro E; Dearnaley D; Eccles DM; Tricker K; Eyfjord J; Falconer A; Foster C; Gronberg H; Hamdy FC; Stefansdottir V; Khoo V; Lindeman GJ; Lubinski J; Axcrona K; Mikropoulos C; Mitra A; Moynihan C; Rennert G; Suri M; Wilson P; Dudderidge T; ; Offman J; Kote-Jarai Z; Vickers A; Lilja H; Eeles RA
    Eur Urol; 2019 Dec; 76(6):831-842. PubMed ID: 31537406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.
    Agalliu I; Gern R; Leanza S; Burk RD
    Clin Cancer Res; 2009 Feb; 15(3):1112-20. PubMed ID: 19188187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homeobox B13 G84E Mutation and Prostate Cancer Risk.
    Nyberg T; Govindasami K; Leslie G; Dadaev T; Bancroft E; Ni Raghallaigh H; Brook MN; Hussain N; Keating D; Lee A; McMahon R; Morgan A; Mullen A; Osborne A; Rageevakumar R; ; Kote-Jarai Z; Eeles R; Antoniou AC
    Eur Urol; 2019 May; 75(5):834-845. PubMed ID: 30527799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
    Lecarpentier J; Silvestri V; Kuchenbaecker KB; Barrowdale D; Dennis J; McGuffog L; Soucy P; Leslie G; Rizzolo P; Navazio AS; Valentini V; Zelli V; Lee A; Amin Al Olama A; Tyrer JP; Southey M; John EM; Conner TA; Goldgar DE; Buys SS; Janavicius R; Steele L; Ding YC; Neuhausen SL; Hansen TVO; Osorio A; Weitzel JN; Toss A; Medici V; Cortesi L; Zanna I; Palli D; Radice P; Manoukian S; Peissel B; Azzollini J; Viel A; Cini G; Damante G; Tommasi S; Peterlongo P; Fostira F; Hamann U; Evans DG; Henderson A; Brewer C; Eccles D; Cook J; Ong KR; Walker L; Side LE; Porteous ME; Davidson R; Hodgson S; Frost D; Adlard J; Izatt L; Eeles R; Ellis S; Tischkowitz M; ; Godwin AK; Meindl A; Gehrig A; Dworniczak B; Sutter C; Engel C; Niederacher D; Steinemann D; Hahnen E; Hauke J; Rhiem K; Kast K; Arnold N; Ditsch N; Wang-Gohrke S; Wappenschmidt B; Wand D; Lasset C; Stoppa-Lyonnet D; Belotti M; Damiola F; Barjhoux L; Mazoyer S; ; Van Heetvelde M; Poppe B; De Leeneer K; Claes KBM; de la Hoya M; Garcia-Barberan V; Caldes T; Perez Segura P; Kiiski JI; Aittomäki K; Khan S; Nevanlinna H; van Asperen CJ; ; Vaszko T; Kasler M; Olah E; Balmaña J; Gutiérrez-Enríquez S; Diez O; Teulé A; Izquierdo A; Darder E; Brunet J; Del Valle J; Feliubadalo L; Pujana MA; Lazaro C; Arason A; Agnarsson BA; Johannsson OT; Barkardottir RB; Alducci E; Tognazzo S; Montagna M; Teixeira MR; Pinto P; Spurdle AB; Holland H; ; Lee JW; Lee MH; Lee J; Kim SW; Kang E; Kim Z; Sharma P; Rebbeck TR; Vijai J; Robson M; Lincoln A; Musinsky J; Gaddam P; Tan YY; Berger A; Singer CF; Loud JT; Greene MH; Mulligan AM; Glendon G; Andrulis IL; Toland AE; Senter L; Bojesen A; Nielsen HR; Skytte AB; Sunde L; Jensen UB; Pedersen IS; Krogh L; Kruse TA; Caligo MA; Yoon SY; Teo SH; von Wachenfeldt A; Huo D; Nielsen SM; Olopade OI; Nathanson KL; Domchek SM; Lorenchick C; Jankowitz RC; Campbell I; James P; Mitchell G; Orr N; Park SK; Thomassen M; Offit K; Couch FJ; Simard J; Easton DF; Chenevix-Trench G; Schmutzler RK; Antoniou AC; Ottini L
    J Clin Oncol; 2017 Jul; 35(20):2240-2250. PubMed ID: 28448241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
    Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.
    Barnes DR; Silvestri V; Leslie G; McGuffog L; Dennis J; Yang X; Adlard J; Agnarsson BA; Ahmed M; Aittomäki K; Andrulis IL; Arason A; Arnold N; Auber B; Azzollini J; Balmaña J; Barkardottir RB; Barrowdale D; Barwell J; Belotti M; Benitez J; Berthet P; Boonen SE; Borg Å; Bozsik A; Brady AF; Brennan P; Brewer C; Brunet J; Bucalo A; Buys SS; Caldés T; Caligo MA; Campbell I; Cassingham H; Christensen LL; Cini G; Claes KBM; ; ; Cook J; Coppa A; Cortesi L; Damante G; Darder E; Davidson R; de la Hoya M; De Leeneer K; de Putter R; Del Valle J; Diez O; Ding YC; Domchek SM; Donaldson A; Eason J; Eeles R; Engel C; Evans DG; Feliubadaló L; Fostira F; Frone M; Frost D; Gallagher D; Gehrig A; Giraud S; Glendon G; Godwin AK; Goldgar DE; Greene MH; Gregory H; Gross E; Hahnen E; Hamann U; Hansen TVO; Hanson H; Hentschel J; Horvath J; ; ; Izatt L; Izquierdo A; James PA; Janavicius R; Jensen UB; Johannsson OT; John EM; Kramer G; Kroeldrup L; Kruse TA; Lautrup C; Lazaro C; Lesueur F; Lopez-Fernández A; Mai PL; Manoukian S; Matrai Z; Matricardi L; Maxwell KN; Mebirouk N; Meindl A; Montagna M; Monteiro AN; Morrison PJ; Muranen TA; Murray A; Nathanson KL; Neuhausen SL; Nevanlinna H; Nguyen-Dumont T; Niederacher D; Olah E; Olopade OI; Palli D; Parsons MT; Pedersen IS; Peissel B; Perez-Segura P; Peterlongo P; Petersen AH; Pinto P; Porteous ME; Pottinger C; Pujana MA; Radice P; Ramser J; Rantala J; Robson M; Rogers MT; Rønlund K; Rump A; Sánchez de Abajo AM; Shah PD; Sharif S; Side LE; Singer CF; Stadler Z; Steele L; Stoppa-Lyonnet D; Sutter C; Tan YY; Teixeira MR; Teulé A; Thull DL; Tischkowitz M; Toland AE; Tommasi S; Toss A; Trainer AH; Tripathi V; Valentini V; van Asperen CJ; Venturelli M; Viel A; Vijai J; Walker L; Wang-Gohrke S; Wappenschmidt B; Whaite A; Zanna I; Offit K; Thomassen M; Couch FJ; Schmutzler RK; Simard J; Easton DF; Chenevix-Trench G; Antoniou AC; Ottini L;
    J Natl Cancer Inst; 2022 Jan; 114(1):109-122. PubMed ID: 34320204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial Cancer Risk in Women With Germline BRCA1 or BRCA2 Mutations: Multicenter Cohort Study.
    de Jonge MM; de Kroon CD; Jenner DJ; Oosting J; de Hullu JA; Mourits MJE; Gómez Garcia EB; Ausems MGEM; Margriet Collée J; van Engelen K; van de Beek I; ; Smit VTHBM; Rookus MA; de Bock GH; van Leeuwen FE; Bosse T; Dekkers OM; van Asperen CJ
    J Natl Cancer Inst; 2021 Sep; 113(9):1203-1211. PubMed ID: 33710348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.
    Gallagher DJ; Gaudet MM; Pal P; Kirchhoff T; Balistreri L; Vora K; Bhatia J; Stadler Z; Fine SW; Reuter V; Zelefsky M; Morris MJ; Scher HI; Klein RJ; Norton L; Eastham JA; Scardino PT; Robson ME; Offit K
    Clin Cancer Res; 2010 Apr; 16(7):2115-21. PubMed ID: 20215531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
    Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations.
    Bancroft EK; Saya S; Page EC; Myhill K; Thomas S; Pope J; Chamberlain A; Hart R; Glover W; Cook J; Rosario DJ; Helfand BT; Hutten Selkirk C; Davidson R; Longmuir M; Eccles DM; Gadea N; Brewer C; Barwell J; Salinas M; Greenhalgh L; Tischkowitz M; Henderson A; Evans DG; Buys SS; ; ; Eeles RA; Aaronson NK
    BJU Int; 2019 Feb; 123(2):284-292. PubMed ID: 29802810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
    Antoniou A; Pharoah PD; Narod S; Risch HA; Eyfjord JE; Hopper JL; Loman N; Olsson H; Johannsson O; Borg A; Pasini B; Radice P; Manoukian S; Eccles DM; Tang N; Olah E; Anton-Culver H; Warner E; Lubinski J; Gronwald J; Gorski B; Tulinius H; Thorlacius S; Eerola H; Nevanlinna H; Syrjäkoski K; Kallioniemi OP; Thompson D; Evans C; Peto J; Lalloo F; Evans DG; Easton DF
    Am J Hum Genet; 2003 May; 72(5):1117-30. PubMed ID: 12677558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
    Rebbeck TR; Mitra N; Wan F; Sinilnikova OM; Healey S; McGuffog L; Mazoyer S; Chenevix-Trench G; Easton DF; Antoniou AC; Nathanson KL; ; Laitman Y; Kushnir A; Paluch-Shimon S; Berger R; Zidan J; Friedman E; Ehrencrona H; Stenmark-Askmalm M; Einbeigi Z; Loman N; Harbst K; Rantala J; Melin B; Huo D; Olopade OI; Seldon J; Ganz PA; Nussbaum RL; Chan SB; Odunsi K; Gayther SA; Domchek SM; Arun BK; Lu KH; Mitchell G; Karlan BY; Walsh C; Lester J; Godwin AK; Pathak H; Ross E; Daly MB; Whittemore AS; John EM; Miron A; Terry MB; Chung WK; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Steele L; Neuhausen SL; Ding YC; Ejlertsen B; Gerdes AM; Hansen Tv; Ramón y Cajal T; Osorio A; Benitez J; Godino J; Tejada MI; Duran M; Weitzel JN; Bobolis KA; Sand SR; Fontaine A; Savarese A; Pasini B; Peissel B; Bonanni B; Zaffaroni D; Vignolo-Lutati F; Scuvera G; Giannini G; Bernard L; Genuardi M; Radice P; Dolcetti R; Manoukian S; Pensotti V; Gismondi V; Yannoukakos D; Fostira F; Garber J; Torres D; Rashid MU; Hamann U; Peock S; Frost D; Platte R; Evans DG; Eeles R; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Hodgson S; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Izatt L; Adlard J; Donaldson A; Ellis S; Sharma P; Schmutzler RK; Wappenschmidt B; Becker A; Rhiem K; Hahnen E; Engel C; Meindl A; Engert S; Ditsch N; Arnold N; Plendl HJ; Mundhenke C; Niederacher D; Fleisch M; Sutter C; Bartram CR; Dikow N; Wang-Gohrke S; Gadzicki D; Steinemann D; Kast K; Beer M; Varon-Mateeva R; Gehrig A; Weber BH; Stoppa-Lyonnet D; Sinilnikova OM; Mazoyer S; Houdayer C; Belotti M; Gauthier-Villars M; Damiola F; Boutry-Kryza N; Lasset C; Sobol H; Peyrat JP; Muller D; Fricker JP; Collonge-Rame MA; Mortemousque I; Nogues C; Rouleau E; Isaacs C; De Paepe A; Poppe B; Claes K; De Leeneer K; Piedmonte M; Rodriguez G; Wakely K; Boggess J; Blank SV; Basil J; Azodi M; Phillips KA; Caldes T; de la Hoya M; Romero A; Nevanlinna H; Aittomäki K; van der Hout AH; Hogervorst FB; Verhoef S; Collée JM; Seynaeve C; Oosterwijk JC; Gille JJ; Wijnen JT; Gómez Garcia EB; Kets CM; Ausems MG; Aalfs CM; Devilee P; Mensenkamp AR; Kwong A; Olah E; Papp J; Diez O; Lazaro C; Darder E; Blanco I; Salinas M; Jakubowska A; Lubinski J; Gronwald J; Jaworska-Bieniek K; Durda K; Sukiennicki G; Huzarski T; Byrski T; Cybulski C; Toloczko-Grabarek A; Złowocka-Perłowska E; Menkiszak J; Arason A; Barkardottir RB; Simard J; Laframboise R; Montagna M; Agata S; Alducci E; Peixoto A; Teixeira MR; Spurdle AB; Lee MH; Park SK; Kim SW; Friebel TM; Couch FJ; Lindor NM; Pankratz VS; Guidugli L; Wang X; Tischkowitz M; Foretova L; Vijai J; Offit K; Robson M; Rau-Murthy R; Kauff N; Fink-Retter A; Singer CF; Rappaport C; Gschwantler-Kaulich D; Pfeiler G; Tea MK; Berger A; Greene MH; Mai PL; Imyanitov EN; Toland AE; Senter L; Bojesen A; Pedersen IS; Skytte AB; Sunde L; Thomassen M; Moeller ST; Kruse TA; Jensen UB; Caligo MA; Aretini P; Teo SH; Selkirk CG; Hulick PJ; Andrulis I
    JAMA; 2015 Apr; 313(13):1347-61. PubMed ID: 25849179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
    Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
    Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.